Search results for "Intensive Care Medicine"

showing 10 items of 2228 documents

Non-invasive management of an acute chest infection for a patient with ALS.

2003

We describe a man diagnosed with non-bulbar amyotrophic lateral sclerosis (ALS) who uses 24-h non-invasive ventilator at home, and assisted cough through the use of the mechanical insufflation-exsufflation (MAC) device (CoughAssist, J.H. Emerson). This was essential for the removal of bronchial secretions in order to provide successful non-invasive management (and indeed less suffering for the patient) during an acute respiratory tract infection with hypoxemia and failure of manually assisted cough.

Artificial ventilationMalemedicine.medical_specialtyRespiratory Therapymedicine.medical_treatmentHypoxemiaIntensive caremedicineHumansAmyotrophic lateral sclerosisIntensive care medicineHypoxiaAcute respiratory tract infectionEmergency TreatmentRespiratory Tract InfectionsAgedRespiratory tract infectionsbusiness.industryRespiratory diseaseAmyotrophic Lateral Sclerosismedicine.diseaseRespiration Artificialrespiratory tract diseasesNeurologyAcute DiseaseNeurology (clinical)Exsufflationmedicine.symptombusinessJournal of the neurological sciences
researchProduct

Effektivit�t pr�klinischer Notfallversorgung Fiktion oder Fakt?

1996

The current increase in the cost of health care must be considered as a severe threat to the prehospital emergency services system. Two examples have been selected--the patient with polytrauma and the patient in cardiac arrest--to demonstrate the dilemma between a need for objective data and the requirements of emergency patients. Study results obtained in trauma patients indicating that total prehospital time, including scene time, is correlated to patient outcome have led to the conclusion that at the scene treatment by emergency physicians may be dispensable. It has, however also been demonstrated that the time required for medical treatment at the scene is equivalent to 20% of the total…

Artificial ventilationmedicine.medical_specialtyEmergency managementbusiness.industryDefibrillationmedicine.medical_treatmentMEDLINEGeneral Medicinemedicine.diseasePolytraumaAnesthesiology and Pain MedicineVentricular fibrillationHealth caremedicineCardiopulmonary resuscitationIntensive care medicinebusinessDer Anaesthesist
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Acetylcholine via Muscarinic Receptors Inhibits Histamine Release from Human Isolated Bronchi

1997

Human bronchi were incubated in organ baths to measure histamine release. The calcium ionophore A23187 (10 mumol/L; 1 min) stimulated histamine release by 148 +/- 28% (n = 11) above the prestimulation level but was ineffective in epithelium-denuded bronchi. Neither bradykinin (0.1 mumol/L) nor compound 48/80 (10 micrograms/ml) triggered the release of histamine from epithelium-intact bronchi. Acetylcholine did not affect spontaneous histamine release (about 2 nmol/g x 5 min) but inhibited A23187-evoked histamine release in an atropine-sensitive manner. Already a concentration as low as 0.1 nmol/L acetylcholine was effective, the maximal inhibition (by 89%) occurred at 100 nmol/L, whereas a …

AtropinePulmonary and Respiratory MedicineAgonistPhysostigminemedicine.medical_specialtyTime Factorsmedicine.drug_classPhysostigmineBradykininBronchiMuscarinic AntagonistsMuscarinic AgonistsCritical Care and Intensive Care MedicineHistamine Releasechemistry.chemical_compoundCulture TechniquesInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansDrug InteractionsCalcimycinDose-Response Relationship DrugIonophoresbusiness.industryOxotremorineImmunoglobulin EReceptors MuscarinicAcetylcholineEndocrinologychemistryAcetylcholinesterase inhibitorDepression ChemicalCholinesterase InhibitorsbusinessAcetylcholineHistaminemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Release of [3H]Acetylcholine in Human Isolated Bronchi: Effect of Indomethacin on Muscarinic Autoinhibition

1995

Receptor-mediated regulation of acetylcholine release in the airways, particularly in humans, remains unclear. In the present study, the tissue content of acetylcholine and release of [3H]acetylcholine were measured in freshly dissected human bronchi obtained at thoracotomy. Large (main and lobar bronchi) and small (segmental and subsegmental bronchi) airways contained considerable amounts of endogenous acetylcholine (300 +/- 50 pmol/100 mg wet weight), whereas significantly less was found in lung parenchyma (60 +/- 30 pmol/100 mg). Isolated small bronchi incubated in an organ bath with the precursor [3H]choline synthesized significant amounts of [3H]acetylcholine (26,000 +/- 4,000 dpm/100 …

AtropinePulmonary and Respiratory Medicinemedicine.medical_specialtyIndomethacinStimulationBronchiIn Vitro TechniquesCritical Care and Intensive Care Medicinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineCholineHumansbusiness.industryOxotremorinerespiratory systemReceptors MuscarinicAcetylcholineElectric StimulationAtropineEndocrinologychemistryTetrodotoxinCholinergicbusinessAcetylcholinemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Treatment challenges and investigational opportunities in autoimmune hepatitis.

2005

New drugs and advances in molecular biology afford opportunities to upgrade the treatment of autoimmune hepatitis. The aims of this study were to define treatment problems, identify possible solutions, and stimulate investigations to improve patient care. A clinical subcommittee of the International Autoimmune Hepatitis Group reviewed current management difficulties and proposed corrective actions. The assessment of new front-line and salvage therapies for adults and children were given top priority. Cyclosporine and mycophenolate mofetil were endorsed as drugs worthy of rigorous study in severe disease, and budesonide was endorsed for study as front-line therapy in mild disease. Diagnostic…

Autoimmune diseaseHepatitismedicine.medical_specialtyHepatologybusiness.industryAUTOIMMUNE/*THERAPYPsychological interventionGastroenterologyAutoimmune hepatitisHepatologymedicine.diseaseSurgeryTransplantationHEPATITISHepatitis AutoimmuneDosing schedulesInternal medicineEpidemiologymedicineHumansIntensive care medicinebusinessGASTROENTEROLOGY/*TRENDSHepatology (Baltimore, Md.)
researchProduct

Choosing the Right Antifungal Agent in ICU Patients

2019

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the phar…

AzolesAntifungal AgentsReviewKidney Function TestsInvasive aspergillosiEchinocandins0302 clinical medicineLiver Function Tests[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineDrug InteractionsPharmacology (medical)030212 general & internal medicineComputingMilieux_MISCELLANEOUSmedia_common[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesIncidenceIncidence (epidemiology)CandidiasisGeneral MedicineSerum concentrationIntensive care patients3. Good healthIntensive Care UnitsPractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCandidiasiNarrative reviewDrug MonitoringInvasive fungi infectionAntifungalDrugmedicine.medical_specialtyIcu patientsmedicine.drug_classmedia_common.quotation_subjectPharmacokineticPolyenesImmunocompromised Host03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careHumansPharmacokinetics[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care medicineIntensive care patient030306 microbiologybusiness.industry[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyInvasive aspergillosisLiver functionbusinessPractical guidelinesInvasive Fungal InfectionsAdvances in Therapy
researchProduct

Laboratory Tests in Crohn’s Disease

2015

Laboratory tests are useful for diagnosing Crohn’s disease, assessing disease activity, identifying complications, and monitoring response to therapy. Their role has been considered limited in the past due to lack of specificity. The introduction of biological therapies in inflammatory bowel disease (IBD) has renewed interest in inflammatory markers, especially C-reactive protein (CRP), given their potential to select responders to these treatments. There are several reasons why laboratory markers have been studied in IBD in the past decades: firstly, to gain an objective measurement of disease activity as symptoms are often subjective; secondly, to avoid invasive (endoscopic) procedures wh…

Biological therapiesCrohn's diseasemedicine.medical_specialtyResponse to therapybusiness.industryObjective measurementDiseasemedicine.diseaseIron sucroseInflammatory bowel diseasemedicineIntensive care medicinebusinessIrritable bowel syndromemedicine.drug
researchProduct

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action

2020

Blood GlucoseAmerican diabetes associationmedicine.medical_specialtybusiness.industryLow density lipoprotein cholesterolCardiovascular outcome trials Cardiovascular prevention Cardiovascular risk Diabetes mellitus type 2 Glucose-lowering drugs Therapeutical targets Blood Glucose Humans Hypoglycemic Agents Cardiovascular Diseases Diabetes Mellitus Type 2 Sodium-Glucose Transporter 2 InhibitorsCall to actionProprotein Convertase Subtilisin/Kexin 9Diabetes Mellitus Type 2Cardiovascular preventionCardiovascular DiseasesHumansHypoglycemic AgentsMedicineCardiology and Cardiovascular MedicinebusinessIntensive care medicineSodium-Glucose Transporter 2 InhibitorsGlycated haemoglobin
researchProduct

Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice

2021

Blood GlucoseGlycated Hemoglobinmedicine.medical_specialtybusiness.industryPharmacology toxicologyGeneral MedicineGlycated Hemoglobin A Humans Blood Glucose Diabetic AngiopathiesRheumatologyDilemmaClinical Practicechemistry.chemical_compoundchemistryInternal medicinemedicineHumansPharmacology (medical)Glycated hemoglobinbusinessIntensive care medicineDiabetic AngiopathiesGlycemic
researchProduct